RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that symptomatic current and former smokers with spirometric values
within the normal range (post-bronchodilator FEV1/FVC≥0.70 and post-BD FVC ≥ 70% predicted
will still derive symptomatic benefit from long-acting bronchodilator therapy even though
they are excluded from current GOLD guideline recommendations.